BCIQ Profiles

Company Profile Report

Iterum antibiotic fails in Phase III for intra-abdominal infections, further driving down shares

Iterum became the latest anti-infective developer to suffer a blow in the market, losing more than a third of its value with a narrow miss on the primary endpoint in a pivotal trial. Still, the company doesn't believe the setback is enough to doom the antibiotic’s potential for a

Read the full 494 word article

How to gain access

Continue reading with a
two-week free trial.